Mixed Th1/Th2/Th17 Responses Induced by Plant Oil Adjuvant-Based B. bronchiseptica Vaccine in Mice, with Mechanisms Unraveled by RNA-Seq, 16S rRNA and Metabolomics
Open Access
Abstract
Background/Objectives: The current Bordetella bronchiseptica (Bb) vaccine, when adjuvanted with alum, does not elicit adequate robust cellular immunity or effective antibody defense against Bb attacks. Unfortunately, antibiotic treatment generally represents an ineffective strategy due to the development of resistance against a broad range of antibiotics. Methods: The present study was designed to investigate the immune response, protective capabilities and underlying mechanisms of a plant oil-based adjuvant E515 formulated with inactivated Bb antigen as a potential vaccine candidate against Bordetella bronchiseptica. Results: Immunization studies revealed that a combination of SO, VE and GS (E515) exhibited a good synergistic adjuvant effect. The E515 adjuvanted Bb vaccine was proven to be highly efficacious and induced a mixed Th1/Th2/Th17 immune response in mice, leading to a significant increase in Bb-specific IgG, IgG1 and IgG2a antibodies, proliferative lymphocyte responses and cytokine levels (by lymphocytes and serum) and effectively induced responses by CD4+ TE, TM cells and B cells. The E515 adjuvant significantly enhanced the immune protection provided by the Bb vaccine in a mice model, as indicated by a reduced bacterial burden in the lungs. Multi-omics sequencing analysis revealed that E515 functions as an adjuvant by modulating critical pathways, including cytokine–cytokine receptor interaction, the IL-17 signaling pathway and the chemokine signaling pathway. This modulation also included interactions with beneficial species of bacteria including Alistipes, Odoribacter and Colidextribacter, as well as energy and lipid-related metabolites, thus highlighting its role as an immunomodulatory agent. Conclusion: Collectively, our results demonstrate the huge potential of E515-Bb vaccine candidates, thus highlighting the vegetable oil original adjuvant E515 as a promising agent for the development of new veterinary vaccines.Keywords
Funding Information
- National Natural Science Foundation of China (32102714, CARS-43-C-2, 2023C02047)
- China Agriculture Research System of MOF and MARA (32102714, CARS-43-C-2, 2023C02047)
- ‘Pioneer’ and ‘Leading Goose’ R&D Program of Zhejiang (32102714, CARS-43-C-2, 2023C02047)
This publication has 53 references indexed in Scilit:
- Enhanced protective efficacy of an OprF/PcrV bivalent DNA vaccine against Pseudomonas aeruginosa using a hydrogel delivery systemBiomedicine & Pharmacotherapy, 2024
- Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infectionAntiviral Research, 2023
- Cytokines and their role as immunotherapeutics and vaccine Adjuvants: The emerging conceptsCytokine, 2023
- Th17 cytokines and factors modulating their activity in patients with pernicious anemiaImmunologic Research, 2023
- Clonal replacement sustains long-lived germinal centers primed by respiratory virusesCell, 2022
- Apigenin attenuates inflammatory response in allergic rhinitis mice by inhibiting the TLR4/MyD88/NF‐κB signaling pathwayEnvironmental Toxicology, 2022
- Histology and metabonomics reveal the toxic effects of kresoxim-methyl on adult zebrafishChemosphere, 2022
- Peucedanum praeruptorum Dunn polysaccharides regulate macrophage inflammatory response through TLR2/TLR4-mediated MAPK and NF-κB pathwaysBiomedicine & Pharmacotherapy, 2022
- Restarting Respiratory Clinical Research in the Era of the Coronavirus Disease 2019 PandemicChest, 2021
- The vaccine adjuvant alum promotes IL‐10 production that suppresses Th1 responsesEuropean Journal of Immunology, 2018